Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference
February 09 2021 - 7:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced participation in a series of 1x1
meetings with institutional investors at the 10th Annual SV Leerink
Global Healthcare Conference, occurring February 24 – 26, 2021.
To schedule a 1x1 meeting with Exicure, please view availability
on the conference page here.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immune-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure’s drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209005101/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024